Home/Filings/4/0001326110-25-000023

4//SEC Filing

SOON-SHIONG PATRICK 4

Accession 0001326110-25-000023

CIK 0001326110other

View on SEC.gov Company Profile

Filed

Feb 24, 7:00 PM ET

Accepted

Feb 25, 9:11 PM ET

Size

24.4 KB

Accession

0001326110-25-000023

Insider Transaction Report

Form 4

Period: 2025-02-22

ImmunityBio, Inc.IBRX

SOON SHIONG PATRICK

DirectorSee remarks10% Owner

Transactions

Exercise/Conversion
Restricted Stock Units
2025-02-22−114,329→ 228,658 total
→ Common Stock (114,329 underlying)
Tax Payment
Common Stock
2025-02-22$3.42/sh−42,071$143,883→ 29,546,190 total
Exercise/Conversion
Common Stock
2025-02-22+114,329→ 29,588,261 total

Holdings

Common Stock
(indirect: See footnote)
261,705,814
Common Stock
(indirect: See footnte)
7,976,159
Common Stock
(indirect: See footnote)
9,986,920
Common Stock
(indirect: See footnote)
5,618,326
Common Stock
(indirect: See footnote)
32,606,985
Common Stock
(indirect: See footnote)
246,412,277
Common Stock
(indirect: See footnote)
8,383,414
Common Stock
(indirect: See footnote)
47,557,934

CALIFORNIA CAPITAL EQUITY, LLC

10% Owner

Transactions

Tax Payment
Common Stock
2025-02-22$3.42/sh−42,071$143,883→ 29,546,190 total
Exercise/Conversion
Common Stock
2025-02-22+114,329→ 29,588,261 total
Exercise/Conversion
Restricted Stock Units
2025-02-22−114,329→ 228,658 total
→ Common Stock (114,329 underlying)

Holdings

Common Stock
(indirect: See footnote)
32,606,985
Common Stock
(indirect: See footnote)
261,705,814
Common Stock
(indirect: See footnote)
8,383,414
Common Stock
(indirect: See footnote)
5,618,326
Common Stock
(indirect: See footnote)
47,557,934
Common Stock
(indirect: See footnote)
246,412,277
Common Stock
(indirect: See footnte)
7,976,159
Common Stock
(indirect: See footnote)
9,986,920

MP 13 Ventures, LLC

10% Owner

Transactions

Tax Payment
Common Stock
2025-02-22$3.42/sh−42,071$143,883→ 29,546,190 total
Exercise/Conversion
Restricted Stock Units
2025-02-22−114,329→ 228,658 total
→ Common Stock (114,329 underlying)
Exercise/Conversion
Common Stock
2025-02-22+114,329→ 29,588,261 total

Holdings

Common Stock
(indirect: See footnote)
246,412,277
Common Stock
(indirect: See footnote)
5,618,326
Common Stock
(indirect: See footnote)
261,705,814
Common Stock
(indirect: See footnte)
7,976,159
Common Stock
(indirect: See footnote)
9,986,920
Common Stock
(indirect: See footnote)
8,383,414
Common Stock
(indirect: See footnote)
47,557,934
Common Stock
(indirect: See footnote)
32,606,985

Nant Capital, LLC

10% Owner

Transactions

Exercise/Conversion
Common Stock
2025-02-22+114,329→ 29,588,261 total
Tax Payment
Common Stock
2025-02-22$3.42/sh−42,071$143,883→ 29,546,190 total
Exercise/Conversion
Restricted Stock Units
2025-02-22−114,329→ 228,658 total
→ Common Stock (114,329 underlying)

Holdings

Common Stock
(indirect: See footnote)
261,705,814
Common Stock
(indirect: See footnote)
8,383,414
Common Stock
(indirect: See footnote)
9,986,920
Common Stock
(indirect: See footnte)
7,976,159
Common Stock
(indirect: See footnote)
246,412,277
Common Stock
(indirect: See footnote)
5,618,326
Common Stock
(indirect: See footnote)
47,557,934
Common Stock
(indirect: See footnote)
32,606,985

Cambridge Equities, LP

10% Owner

Transactions

Tax Payment
Common Stock
2025-02-22$3.42/sh−42,071$143,883→ 29,546,190 total
Exercise/Conversion
Common Stock
2025-02-22+114,329→ 29,588,261 total
Exercise/Conversion
Restricted Stock Units
2025-02-22−114,329→ 228,658 total
→ Common Stock (114,329 underlying)

Holdings

Common Stock
(indirect: See footnote)
246,412,277
Common Stock
(indirect: See footnote)
8,383,414
Common Stock
(indirect: See footnote)
261,705,814
Common Stock
(indirect: See footnte)
7,976,159
Common Stock
(indirect: See footnote)
5,618,326
Common Stock
(indirect: See footnote)
9,986,920
Common Stock
(indirect: See footnote)
47,557,934
Common Stock
(indirect: See footnote)
32,606,985

Footnotes (11)

[F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.
[F10]Shares held by NantCancerStemCell, LLC ("NCSC"). NantBio is the majority stockholder and an affiliate of NCSC and may be deemed to have beneficial ownership of the securities held by NCSC. NantWorks is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the securities held by NantBio and its affiliates. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantBio and its affiliates.
[F11]Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.
[F2]On February 22, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 21, 2025 was the settlement price used to calculate the shares withheld.
[F3]Shares held by Nant Capital, LLC, an investment vehicle of the reporting person ("Nant Capital").
[F4]Shares held by Cambridge Equities, LP ("Cambridge Equities"). MP 13 Ventures, LLC ("MP 13 Ventures") is the general partner of Cambridge Equities and may be deemed to have beneficial ownership of the shares held by Cambridge Equities. The reporting person is the sole member of MP 13 Ventures and has voting and dispositive power over the shares held by Cambridge Equities.
[F5]Shares held by NantBio, Inc. ("NantBio"). NantWorks, LLC ("NantWorks") is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the shares held by NantBio. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the shares held by NantBio.
[F6]Shares held by California Capital Equity, LLC ("CalCap"). The reporting person owns all of the equity interests of CalCap and has voting and dispositive power over the shares held by CalCap.
[F7]Shares held by the Chan Soon-Shiong Family Foundation, an exempt corporation organized under the laws of the State of Delaware (the "Foundation"). The Foundation has the sole power to vote and direct the disposition of all shares directly owned by the Foundation, except to the extent it may be deemed to share such power with the reporting person by virtue of the reporting person's control over the Foundation. The reporting person serves as Chairman of the Foundation.
[F8]Shares held by NantWorks, LLC ("NantWorks"). CalCap directly owns all of the equity interests of NantWorks and may be deemed to have beneficial ownership of the securities held by NantWorks. The reporting person directly owns all of the equity interests of CalCap and may be deemed to have voting and dispositive power over the securities held by NantWorks.
[F9]Shares held by NantMobile, LLC ("NantMobile"). NantWorks is the majority stockholder and an affiliate of NantMobile and may be deemed to have beneficial ownership of the securities held by NantMobile. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantMobile.

Documents

1 file

4
wk-form4_1740535889.xmlPrimary
FORM 4

Issuer

ImmunityBio, Inc.

CIK 0001326110

→

Entity typeother

Related Parties

filerCIK 0001189020

Filing Metadata

Form type: 4
Filed: Feb 24, 7:00 PM ET
Accepted: Feb 25, 9:11 PM ET
Size: 24.4 KB

View on SEC.gov